Evidence map›Paper›PMID 41827627›Full record

ArticleHealthcare (Basel, Switzerland)2026

Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework.

Attila Imre, Balázs Nagy, Rok Hren

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Attila ImreCenter for Health Technology Assessment, Semmelweis University, 1085 Budapest, Hungary.ORCID 0009-0004-0110-8395
Balázs NagyCenter for Health Technology Assessment, Semmelweis University, 1085 Budapest, Hungary.
Rok HrenSyreon Research Institute, 1142 Budapest, Hungary.

Funding

European Union Horizon EU IMMUTOL project 101080562
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced therapy developmentcost-effectivenessearly-stage health technology assessmentmultiple sclerosisrisk-adjusted net present valuetolerogenic gene therapy

Identifiers

PMID41827627
PMCPMC12985023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.